cell-cell commun via gap junction plai kei role carcinogenesi growth control on gap junction protein connexin cx26 consid tumor suppressor variou cancer studi express cx26 analyz human lung cancer reduc mrna express observ lung cancer cell line examin northern blot analysi rt-pcr 138 primari carcinoma compris subtyp analyz immunohistochemistri case exhibit express cx26 wherea case cx26 stain posit addition associ cx26 protein express higher grade tumor found whole tumor sampl 0.028 statist signific correl observ tumor stage tumor size node statu squamou cell carcinoma tumor higher stage grade link higher express cx26 0.015 0.017 respect explor mechan respons downregul cx26 treat lung cancer cell line h2170 h226 demethyl agent 5-aza-2'-deoxycytidin found reexpress cx26 mrna methyl statu cell line analyz pcr amplif bisulfit modifi dna sequenc heterogen methyl pattern turn result suggest inactiv cx26 lung cancer explain promot methyl
gefitinib shown meaning antitumor activ toler toxic chemotherapi-refractori nsclc previou studi moreov egfr express fail show correl respons attempt identifi predict marker respons investig tumor express kei signal molecul egfr egfr p-egfr p-akt p-erk p-stat3 immunohistochemistri analyz correl respons patient receiv gefitinib 250 mg/dai chemotherapi-refractori nsclc partial respons 21.5 stabl diseas 32.3 progress diseas 32.3 median durat overal surviv time progress 6.7 month 2.8 month respect immunohistochemistri perform patient evalu tissu specimen egfr overexpress 32.4 p-egfr posit 26.5 express p-akt p-erk p-stat3 posit 38.2 79.4 respect egfr express correl p-egfr downstream molecul egfr p-egfr statu correl respons posit express p-erk significantli associ poor respons 38.1 14.3 0.046 furthermor tumor posit p-akt neg p-erk nuclear express exhibit best respons wherea respons opposit [p-akt p-erk case intens nuclear stain p-akt associ prolong ttp 0.25 confid interv [ci] 0.08-0.79 0.018 0.16 0.04-0.62 0.008 result support assumpt gefitinib respons predict activ egfr downstream molecul p-akt p-erk
her-2/neu oncogen activ gene amplif protein overexpress document sever human malign irrespect protein overexpress her-2/neu gene amplif rare lung cancer studi preval clinicopatholog implic earli stage non-small cell lung cancer ncslc neuroendocrin tumour net lung lack evalu her-2/neu abnorm 345 stage nsclc 207 stage i-iii net lung divers histolog type us immunohistochemistri fluoresc situ hybrid select case overal her-2/neu immunoreact detect 345 nsclc 207 net gene amplif 7.4 immunoreact tumour high-level amplif her-2/neu gene chromosom ratio 4.0 adenocarcinoma squamou-cell carcinoma larg-cell neuroendocrin carcinoma lcnec low-level amplif her-2/neu gene chromosom ratio 2.0 4.0 squamou-cell carcinoma lcnec none test carcinoid sclc show gene amplif gene amplifi case exhibit membran label relationship found gene amplif protein overexpress patient' surviv clinicopatholog variabl her-2/neu gene amplif protein overexpress close correl lung carcinoma bear prognost implic among neuroendocrin tumour lcnec show slightli higher preval her-2/neu gene amplif protein overexpress
examin cyp1a1 t6235c a4889g polymorph san francisco bai area african american latino newli diagnos primari lung cancer septemb 1998 novemb 2002 ag-gender-ethnic frequenc-match control ow mainli rapid mortal case overal percentag case genotyp latino african american respect cyp1a1 variant genotyp latino 104 case 278 control african american 226 case 551 control frequenc control 0.23 0.02 african american 0.38 0.29 latino latino overal invers odd ratio 0.51 0.32-0.81 variant genotyp result invers interact smoke nonsmok genotyp slight elev 1.5 0.59-3.7 pack-year histori 0.20 0.06-0.70 0.21 0.06-0.81 time 1/5 odd expect smoke genotyp independ lung cancer risk factor african american interact similar magnitud statist signific result similar invers interact cyp1a1 variant smoke-associ lung cancer risk latino causal due undetect bia confound repres uniqu linkag disequilibrium lung cancer locu cyp1a1 highli admix popul
human doc-2/dab2 interact protein gene hdab2ip novel member ra gtpase-activ gene famili known act tumor suppressor gene inactiv methyl prostat breast cancer establish previous methyl-specif pcr msp promot region m2a m2b region hdab2ip examin hdab2ip methyl statu breast cancer analyz methyl express statu hdab2ip lung cancer methyl statu hdab2ip examin lung cancer cell line us bisulfit sequenc msp express examin us convent real-time rt-pcr methyl found invers correl express confirm msp us examin hdab2ip methyl statu lung cancer aberr methyl detect m2a region lung cancer cell line primari tumor m2b line tumor gene express restor methyl cell line supplement 5-aza-2'-deoxycytidin confirm methyl respons downregul examin relationship hdab2ip methyl clinico-patholog featur lung cancer found hdab2ip methyl associ advanc diseas stage result demonstr hdab2ip methyl frequent present lung cancer plai kei role hdab2ip silenc hdab2ip methyl us biomark diseas stage reflect degre clinico-patholog malign lung cancer
purpos epidemiolog studi suggest consumpt green tea protect effect develop sever cancer preclin studi green tea polyphenol compon demonstr antimutagen anticarcinogen activ inhibit growth tumor cell line anim tumor model includ lung cancer green tea chemoprevent properti enhanc cytotox chemotherapeut agent demonstr trial design determin maximum toler dose mtd green tea extract gte patient advanc lung cancer method total patient advanc lung cancer regist receiv onc-daili oral dose gte start dose 0.5 g/m2 per dai acceler dose-escal scheme result schedul mtd gte g/m2 per dai dose gte well toler grade toxic dose-limit toxic diarrhea nausea hypertens object respons trial seven patient stabl diseas rang week patient remain therapi longer week due develop progress diseas conclus studi suggest rel nontox dose g/m2 per dai gte like limit activ cytotox agent studi gte singl-agent establish malign warrant studi focu potenti chemoprevent chemotherapi-enhanc properti gte
14-3-3 protein plai import role wide rang vital regulatori process includ signal transduct apoptosi cell cycl progress dna replic mammalian cell 14-3-3 isoform beta gamma epsilon eta sigma theta zeta identifi seem distinct tissu local isoform-specif function previou studi shown 14-3-3 protein level higher human lung cancer compar normal tissu unclear howev 14-3-3 isoform overexpress cancer studi level seven 14-3-3 isoform examin rt-pcr western blot show messag two isoform 14-3-3epsilon zeta detect normal tissu lung cancer biopsi howev four isoform 14-3-3beta gamma sigma theta addit 14-3-3epsilon zeta present abund express frequenc 14-3-3beta gamma sigma theta isoform biopsi examin respect data immunohistochem stain western blot consist rt-pcr result given preval elev 14-3-3 express human lung cancer propos protein involv lung cancer tumorigenesi specif 14-3-3 protein us marker lung cancer diagnosi target therapi
inactiv p16ink4a gene through promot hypermethyl frequent observ non small cell lung cancer howev variou studi shown controversi correl p16ink4a hypermethyl cigarett smoke recent report show human papillomarviru hpv 16/18 infect associ develop nonsmok femal lung cancer taiwan specul hpv infect link p16ink4a hypermethyl verifi influenc environment exposur includ cigarett smoke environment carcinogen exposur hpv infect p16ink4a hypermethyl tumor 162 lung patient includ smoke male nonsmok male nonsmok femal subject p16ink4a hypermethyl analysi methyl-specif pcr result show p16ink4a hypermethyl detect 59.7 smoke male 36.6 nonsmok male 60.3 nonsmok femal lung tumor result seem reveal gender cigarett smoke both possess equal influenc p16ink4a hypermethyl result led specul hpv infect promot p16ink4a hypermethyl nonsmok femal lung cancer patient data p16ink4a hypermethyl frequenc nonsmok femal lung tumor hpv infect high compar hpv infect fact correl hpv infect p16ink4a hypermethyl observ nonsmok femal lung tumor 0.017 smoke male nonsmok male lung tumor moreov revers correl p16ink4a immunostain p16ink4a promot hypermethyl observ nonsmok femal lung tumor result strongli suggest involv hpv infect lung tumorigenesi nonsmok femal cancer patient taiwan mediat least part through increas hypermethyl caus p16ink4a inactiv
paclitaxel antiangiogen properti mechan enhanc sensit endotheli cell ec drug establish aim studi compar distribut paclitaxel ec cell type assess effect low dose paclitaxel cox-2 express determin combin effect paclitaxel cox-2 inhibitor angiogenesi vitro patient cancer exposur low concentr [3h]-paclitaxel uptak radioact time higher ec cell type expos human umbil vein ec low nanomolar 1-50 concentr paclitaxel enhanc cox-2 express 2-fold measur elisa combin treatment paclitaxel cox-2 inhibitor ns-398 result increas antiendotheli effect compar agent alon assess biolog effect combin treatment vivo cancer patient treat prolong intraven infus paclitaxel mg/m2/dai cox-2 inhibitor celecoxib 400 p.o bid plasma angiogen activ drug level measur treatment well toler provid steadi-state concentr paclitaxel plasma potent plasma antiendotheli effect observ find suggest antiangiogen effect paclitaxel due preferenti accumul ec low dose paclitaxel combin cox-2 inhibitor attract antiangiogen antitumor strategi deserv evalu clinic trial
resist chemotherapi intrins present most nonsmal-cell lung carcinoma nsclc paramet yet determin predict respons chemotherapi howev mrp1 multidrug resist-associ protein suspect plai import role resist treatment genet basi resist clearli understood result chromosom reassort catalyz aneuploidi aim studi investig mrp1 express concurr dna ploidi analysi order evalu link mrp1 express chromosom mrp1 gene locat aberr nsclc befor treatment eighti-four surgic tumor specimen select sampl contain carcinomat cell sampl normal bronchial epithelium studi sampl stain mrp1 fitc indirect stain propidium iodid analyz flow cytometri fifti tumor contain least dna-aneuploid clone percentag mrp1-posit cell higher dna-aneuploid cell 0.0003 tumor express mrp1 level express 3-fold higher dna-aneuploid cell dna-diploid cell normal bronchial cell well carcinomat cell &lt 0.0001 fish analysi tumor imprint us chromosom alpha-satellit centromer probe demonstr significantli frequent gain chromosom dna-aneuploid tumor result suggest mrp1 overexpress nsclc consequ chromosom reassort catalyz aneuploidi dna-aneuploid tumor requir differ treatment modal appli dna-diploid tumor
indol-3-carbinol i3c compound present glucobracissin crucifer veget anticanc activ line epidemiolog evid suggest benefici effect consumpt crucifer veget cancer incid progress precis target indol-3-carbinol determin examin effect i3c prostat cancer well-defin r3327 model us copenhagen rat transplant cell line mat-lylu cell line deriv tumor copenhagen rat androgen independ metastas lung lymph node tumor induc copenhagen rat inject mat-lylu subcutan anim treat i3c administ intraperiton intraven order achiev maxim system exposur departur tradit chemoprevent rout indol-3-carbinol compound incorpor diet result indic i3c inhibit incid growth metastas mat-lylu cell both i.p i.v inject i3c equal effect statist analysi kaplan-meier curv clearli indic tumor-free overal surviv benefit result treatment i3c studi show first time i3c inject form anti-prostat cancer activ
thymidin kinas tk1 pyrimidin metabol pathwai enzym involv salvag dna synthesi cell cycl-depend marker develop anti-tk1 monoclon/polyclon ab rais 15-amino acid synthet peptid kpgeavaarklfapq correspond part c-terminu human tk1 ab us both serolog immunohistochem detect tk1 number cancer diseas studi examin tk1 concentr serum stk1 250 preoper non-small cell lung cancer patient nsclc includ 188 non-metastat group metastat patient group serum healthi individu us control concentr stk1 preoper nsclc patient significantli higher stk1 healthi individu p&lt 0.0001 group preoper stk1 concentr significantli higher patient tumour size compar tumour size 0.042 t3-t4 compar t1-t2 0.01 signific differ stk1 concentr patient tumour stage stage 0.057 found significantli higher stk1 concentr patient stage iii compar stage i-ii 0.025 signific differ stk1 concentr found patient group concern tumour size tumour stage patient adenocarcinoma squamou cell carcinoma scc studi chang stk1 concentr individu on month oper metastat subject group tumour-free subject group group concentr stk1 on month oper significantli declin compar concentr stk1 preoper p&lt 0.001 group howev signific decreas stk1 concentr found on month oper conclud stk1 prognost valu reliabl marker monitor respons surgeri nsclc patient
imatinib mesyl inhibitor tyrosin kinas includ bcr-abl kit inhibit growth inhibit small cell lung cancer sclc cell line vitro howev clinic trial imatinib mesyl alon patient sclc result unsatisfactori outcom vitamin menaquinon-4 vk2 induc apoptosi differenti leukemia cell recent report vk2 induc apoptosi lung cancer cell line present studi focus vitro combin effect imatinib mesyl plu vk2 sclc cell line lu-139 lu-130 nci-h69 nci-h128 treatment imatinib mesyl vk2 result suppress cell growth dose-depend manner cell line test inhibitori concentr ic50 imatinib mesyl rang 17-29 microm wherea ic50 vk2 rang 16-64 microm combin treatment imatinib mesyl plu vk2 result pronounc inhibit cell growth morpholog featur cell treat imatinib mesyl vk2 typic apoptosi vk2 safe medicin promin advers effect treatment patient sclc deriv therapeut benefit combin imatinib mesyl vk2
present work analyz gene pattern profil squamou non-small cell lung cancer nsclc versu normal lung epitheli tissu mean cdna microarrai addit cdna microarrai analys quantit rt-pcr immunohisto-chemic analys us valid result obtain data enabl gene select look gene detect express tumor express normal sampl invers addition gene detect overexpress tumor compar normal tissu specimen gene yet suspect influenc nsclc biologi gene involv cell prolifer cyclin signal transduct smarcc2 tm4sf3 apoptosi cflar/flip cell cytoskeleton cytokeratin-14 alpha-tubulin isoform s100a10 cell adhes jup invas cathepsin biolog process oaz1 ighg3 scya5/rant beta-sarcoglycan transcobalamin conclus identifi number gene differenti express squamou nsclc compar normal lung epitheli tissu gene involv invas us prognost marker other like cflar/flip constitut therapeut target
purpos evalu efficaci toxic profil combin docetaxel prolong gemcitabin infus front-line chemona patient advanc non-small-cell lung cancer nsclc patient method total chemona patient diagnos advanc nsclc accord ajcc/tnm classif system includ present studi treatment consist 1000 mg/m gemcitabin given 100-min continu infus mg/m per min dai cours mg/m docetaxel 60-min infus dai repeat cours everi dai result ecog perform statu patient follow patient two-dimension measur diseas median ag year rang 41-75 year patient squamou cell carcinoma adenocarcinoma larg-cell carcinoma patient present stage iiib diseas respect stage diseas on metastat site total 220 cours administ median five cours per patient patient assess respons partial remiss 13-39 patient diseas remain stabl diseas progress observ median time diseas progress month median surviv time month year patient remain aliv main grade 3/4 toxic accord scale consist neutropenia asthenia peripher edema dyspnea diarrhea conclus prolong gemcitabin infus combin docetaxel well toler efficaci similar chemotherapeut scheme us nsclc treatment howev prolong infus gemcitabin appear result improv outcom toxic versu standard dose rate
background sought evalu toxic efficaci altern week schedul paclitaxel gemcitabin patient advanc non-small-cell lung cancer nsclc method patient mean ag year rang 27-73 year receiv paclitaxel 100 mg/m i.v infus dai altern gemcitabin 1000 mg/m dai 36-dai cycl respons evalu three cycl propos six cycl result total 116 cycl administ mean 4.25 cycl per patient haematolog toxic slight febril neutropenia neutropenia grade iii-iv non-haematolog toxic includ arthromyalgia grade neurotox grade iii object respons stabl diseas diseas progress median durat respons month 5-11 month median progress-free surviv month 4-11 month median overal surviv month 7-17 month surviv year conclus regimen altern weekli paclitaxel gemcitabin feasibl patient advanc nsclc show lower toxic profil compar platinum-base combin make novel scheme attract patient
studi demonstr chemoimmunotherapi us s-1 novel oral fluoropyrimidin anticanc drug combin lentinan lnt beta --> glucan effect vivo clarifi augment function dendrit cell dc vivo vitro surviv period colon-26-bear mice treat s-1 lnt significantli prolong mice treat s-1 alon &lt 0.05 hand lnt prolong surviv period combin s-1 colon-26-bear athym mice frequenc cd86+ dc infiltr colon-26 increas mice treat s-1 lnt splenic dc harvest mice treat s-1 lnt show potent t-cell prolifer activ dc mice treat s-1 alon &lt 0.05 furthermor activ cytotox lymphocyt ctl splenocyt s-1 lnt-treat mice specif potent ctl mice treat s-1 alon &lt 0.05 result suggest modul specif immun lnt signific role enhanc antitumor effect through modif function demonstr dc plai import role chemotherapi combin therapi s-1 lnt present promis chemoimmunotherapi lead better surviv cancer patient
sever chromosom region recurr amplifi delet lung tumor littl known underli gene import mediat tumor format progress lung cancer rb1-ccnd1-cdkn2a pathwai involv g1-s transit damag tumor present studi local novel amplicon lung tumor fragment 0.5 12q13.3-q14.1 us compar genom hybrid cgh cdna microarrai approach enabl identifi 10-15 gene most consist amplif semiquantit rt-pcr analys gene region show four cdk4 cyp27b1 mettl1 tsfm highli up-regul immunohistochem ihc analysi 141 tumor sampl tissu microarrai show cdk4 express high level lung tumor six 21.4 tumor high cdk4 express shown fluoresc situ hybrid fish contain 12q13.3-q14.1 amplif cdk4 posit correl found gene copi number fish cgh arrai mrna express rt-pcr level protein express ihc cdk4 express correl cdkn2a methyl statu amplif cdk4 describ tumor type role lung cancer remain elucid cdk4 amplif seem rel rare event 4.3 lung tumor indic signific rb1-ccnd1 pathwai lung tumorigenesi
suscept gastric cancer part attribut inter-individu variabl metabol activ detoxif carcinogen context polymorph gstm1 gene extens studi seventeen report detail possibl associ gstm1 delet gastric cancer publish order examin risk gastric cancer associ gstm1 null genotyp meta-analysi publish case-control studi undertaken us random effect model two studi exclud becaus data miss result princip outcom measur odd ratio risk gastric cancer pool studi identifi overal odd ratio gastric cancer risk associ gstm1 defici 1.24 confid interv 1.00-1.54 furthermor pool four studi detail possibl interact gstm1 statu smoke habit gastric cancer risk overal estim odd ratio 2.93 confid interv 1.56-5.47 smoker gstm1 defici compar non-smoker gstm1 normal genotyp emerg result suggest gstm1 statu probabl effect risk gastric cancer per modul tobacco-relat carcinogenesi gastric cancer greater attent paid design futur studi well design popul-base control studi consid possibl confound risk factor base sampl size commensur detect small genotyp risk allow definit conclus
investig characterist lung adenocarcinoma growth behavior establish cell line rat lung cancer nara rlcnr tumor induc n-nitrosobi 2-hydroxypropyl amin bhp rat clone show epitheli cell morpholog grow sheet cultur approxim doubl time 19.2 ultrastructur rlcnr contain lamellar bodi cytoplasm microvilli present free cell surfac line featur well-develop desmosom modal chromosom number same normal rat cell frequenc establish 80.5 evalu tumorigen appropri number cell transplant syngen rat tumor format occur genet analys reveal rlcnr ggt gat mutat codon ki-ra p53 alter p16 gene express lost associ hypermethyl cpg site upstream region gene result indic present newli establish cell line origin alveolar type lesion lung us investig vivo growth mechan especi tumor progress lung adenocarcinoma low malign potenti
role clinic signific circul tumor cell tumor dna plasma yet clarifi present studi compar rate detect tumor-deriv dna buffi coat plasma tumor-bear rat attempt correl rate progress tumor inject dhd/k12-prob cancer cell subcutan bd-ix rat divid anim six group accord time inject tumor cell euthanasia euthanasia macroscop metastas assess sampl blood lung collect us mutant allel-specif amplif pcr detect tumor-deriv dna detect tumor dna lung sampl first week inocul plasma third week buffi coat fifth week anim analyz 11th week macro- micrometastas lung regardless group rate pcr-posit plasma sampl significantli higher circul tumor cell 0.005 anim metastas differ statist signific 0.008 howev neither detect tumor dna plasma nor presenc circul tumor cell strongli correl presenc metastas cell-free tumor dna detect sooner frequent circul tumor cell dissemin tumor dna plasma seem much common detect hematogen tumor cell spread colorect cancer
sti571 imatinib select inhibit bcr/abl pdgfr c-kit kinas activ report larg proport small cell lung cancer sclc cell line tumor express c-kit sti571 inhibit tumor cell growth investig therapeut efficaci sti571 alon combin chemotherapi human sclc cell tumor xenograft nude mice level c-kit mrna express variabl sclc tumor posit xenograft c-kit protein detect immunohistochemistri xenograft tumor pdgfralpha pdgfrbeta detect immunohistochemistri sti571 induc inhibit prolifer sclc6 cell line induc apoptosi contrast combin etoposid topotecan growth inhibit sclc6 cell induc sti571 increas apoptot dna fragment four human sclc xenograft sclc6 sclc61 sclc74 sclc108 transplant mice intraperiton inject sti571 observ growth inhibit sclc6 sclc61 sclc108 tumor respect signific inhibit sclc74 tumor growth mice bear respons sclc tumor observ increas growth inhibit induc chemotherapi etoposid ifosfamid topotecan concomit continu administr sti571 associ increas toxic death sclc6-bear mice receiv sequenti treatment observ reduct toxic death decreas synergist antitumor efficaci conclus efficaci sti571 alon sclc xenograft tumor variabl depend c-kit express moreov signific increas chemotherapi-induc growth inhibit obtain concomit administr sti571 carefulli investig sclc patient
role platelet tumor progress metastasi recogn mechan action remain unclear five human lung cancer cell line a549 crl 2066 crl 2062 htb 183 htb 177 murin lewi lung carcinoma lcc cell line vivo model metastasi us investig platelet-deriv microvesicl pmv circular fragment shed surfac membran activ platelet exosom releas platelet alpha-granul contribut metastat spread found pmv transfer platelet-deriv integrin cd41 most lung cancer cell line test stimul phosphoryl mitogen-activ protein kinas p42/44 serin/threonin kinas well express membran type 1-matrix metalloproteinas mt1-mmp pmv chemoattract cell line highli metastat a549 cell exhibit strongest respons a549 cell pmv shown stimul prolifer upregul cyclin express increas tran-matrigel chemoinvas furthermor cell pmv stimul mrna express angiogen factor mmp-9 vascular endotheli growth factor interleukin-8 hepatocyt growth factor well adhes fibrinogen human umbil vein endotheli cell intraven inject murin pmv-cover llc cell syngen mice result significantli metastat foci lung llc cell bone marrow control anim inject lcc cell cover pmv base find suggest pmv plai import role tumor progress/metastasi angiogenesi lung cancer
purpos examin efficaci uft oral 5-fluorouracil deriv agent post-oper adjuv therapi patholog stage non-small-cell lung cancer nsclc becaus previou random studi suggest efficaci earli-stage nsclc patient patient method patient complet resect p-stage adenocarcinoma squamou cell carcinoma elig total 332 patient random surgeri-alon group control group treatment group uft 400 mg/m year surgeri uft group stratif histolog type result patient 8-year surviv rate uft group 82.2 73.0 control group 75.9 61.2 respect statist signific improv surviv achiev uft administr 0.105 patient 8-year surviv rate uft group 120 85.2 79.5 respect seem better control group 121 79.2 64.0 respect 0.081 squamou cell carcinoma patient differ surviv control group uft group 0.762 pt1 patient 8-year surviv rate uft group 83.6 82.1 respect significantli better control group 77.9 57.6 respect 0.036 uft significantli effect pt2 patient pt1 adenocarcinoma patient uft administr markedli improv surviv 0.011 conclus post-oper uft administr significantli improv post-oper surviv p-stage nsclc patient subset analys suggest uft effect pt1n0m0 adenocarcinoma patient
background phase trial compar docetaxel-cisplatin vinorelbin-cisplatin both first-line therapi follow cross-over progress singl-agent vinorelbin docetaxel advanc non-small-cell lung cancer nsclc method overal 115 patient receiv docetaxel mg/m cisplatin 100 mg/m both dai everi week arm 118 vinorelbin mg/m /week dai cisplatin 100 mg/m dai everi week arm six cycl subsequ maintain monotherapi docetaxel vinorelbin cross-over diseas progress vinorelbin mg/m dai docetaxel 100 mg/m dai both everi week primari point overal respons rate orr result patient characterist balanc median follow-up 8.8 month first-line respons rate 33.9 26.3 0.20 arm respect durat respons similar 8.2 versu 8.4 month median time progress month both median surviv versu month 0.38 3-year surviv versu versu versu signific howev low number long-term survivor statist signific reach overal almost half patient cross second-line therapi respons vinorelbin 11.2 partial respons docetaxel consid safeti profil occurr febril neutropenia 9.6 26.3 treatment-relat mortal 2.5 8.5 conclus trend favour arm orr statist signific reach consist previou report studi suggest activ first-line advanc nsclc second-line vinorelbin doe provid addit clinic benefit alreadi shown studi us first-line provid better percentag long-term survivor despit absenc efficaci second-line studi
background taxoter docetaxel dose mg/m everi week standard therapi pretreat non-small-cell lung cancer nsclc aim studi evalu safeti profil two schedul docetaxel administr everi week versu weekli patient pretreat nsclc patient method februari 2000 februari 2001 125 patient local advanc metastat nsclc randomis failur previou platinum-base regimen receiv docetaxel mg/m administ everi week dq3w docetaxel mg/m given weekli week follow week rest dqw safeti evalu focus grade 3-4 neutropenia febril neutropenia nausea-vomit asthenia result patient' characterist well balanc arm most common nation cancer institut common toxic criteria nci-ctc grade 3-4 toxic neutropenia occur 48.4 dq3w patient versu 15.9 dqw patient 0.001 addit febril neutropenia observ 6.5 patient dq3w versu dqw grade 3-4 asthenia frequent dqw non-haematolog toxic rare regard efficaci trend better diseas control rate dq3w 32.2 versu 25.4 dqw median time progress surviv rather similar both arm respect 2.1 month rang 2-3.2 5.8 month rang 4.0-7.0 dq3w 1.8 month rang 1.6-2.3 5.5 month rang 3.7-6.6 dqw conclus both schedul favour safeti profil signific lower rate sever neutropenia observ weekli arm both regimen similar efficaci weekli regimen consid good altern patient risk sever neutropenia
background purpos studi compar qualiti life overal toxic patient advanc non-small-cell lung cancer nsclc treat vinorelbin-gemcitabin carboplatin-paclitaxel taxol patient method total 165 previous untreat patient random two regimen qualiti life assess lung cancer symptom scale lcss overal toxic secondari efficaci point evalu standard criteria result signific differ overal qualiti life two treatment neutropenia thrombocytopenia peripher neuropathi alopecia common arm wherea constip frequent arm respons rate 14.6 arm 16.9 arm median surviv time 7.8 8.6 month year surviv rate 38.4 31.9 respect conclus patient treat experienc lower toxic overal qualiti life similar both arm efficaci seem compar studi show viabl altern platinum-base chemotherapi patient advanc nsclc
background small cell lung cancer sclc carri poor prognosi recent advanc chemotherapi produc long-term survivor despit recurr common patient requir high level surveil given femal gender favor prognost factor patient sclc women becom lung cancer survivor import consid site metastasi restrict women case present 42-year old previous diagnos sclc present isol recurr sclc ovari case report isol recurr sclc ovari review literatur conclus system relaps recurr occur patient isol metastasi occur consid femal patient histori small cell lung cancer
concept field canceris propos explain develop second primari tumour upper aerodigest tract format blood vessel angiogenesi shown accompani oral diseas progress howev littl known potenti role indic field canceris aim studi compar angiogen profil normal oral mucosa oral cancer patient sampl cancer-free patient seek evid differ term field chang oral mucos tissu obtain oral cancer patient site least distant primari tumour compar normal oral mucosa non-cancer patient vascular tissu investig immunohistochem us four antibodi three method quantit vascular significantli higher group four marker p&lt 0.01 significantli higher indic vascular found patient smoker/drinker group p&lt 0.05 increas vascular provid rational anti-angiogen drug therapi tertiari prevent
success surgeri remov primari tumor compromis subsequ outgrowth metastas recogn primari tumor secret antiangiogen factor suppress outgrowth daughter metastas accord show here surgic remov primari el-4 lymphoma led mark decreas level circul angiostatin endostatin promot growth distant nodular tumor express vector encod angiostatin endostatin formul poli-n-vinyl pyrrolidon pvp inject tibiali gastrocnemia muscl lead express angiostatin endostatin muscl fiber high level biolog activ exogen protein secret circul intramuscular gene therapi angiostatin endostatin plasmid significantli inhibit tumor vascular induc tumor cell apoptosi therebi suppress growth secondari subcutan dissemin metastat tumor lung liver simultan intramuscular deliveri both angiostatin endostatin plasmid significantli prolong surviv mice remov primari tumor result suggest intramuscular gene transfer angiostatin endostatin serv prophylact cancer-prevent strategi combat recurr cancer surgic resect primari tumor
time period 1988-2000 case-case studi environment factor lung cancer risk conduct montevideo uruguai studi design order establish possibl differ squamou cell carcinoma scc small cell carcinoma sclc lung relat tobacco smoke three hundr nineti on 391 patient small cell carcinoma compar 1187 patient squamou cell carcinoma regard sex studi includ small number women sclc scc sclc associ higher risk smoke statu smoke intens cumul exposur tobacco smoke compar scc three tobacco variabl significantli differ both cell type men smoke durat significantli higher among sclc compar scc women decreas ag start smoke proport sclc increas expens scc final type tobacco cigarett differ cell type both sex note tobacco variabl associ increas risk among scc cell type compar sclc result suggest sclc displai strongest relat tobacco smoke scc
lung screen studi lss pilot studi design assess feasibl conduct larg scale random control trial rct low radiat dose spiral comput tomographi ldct versu chest x-rai cxr lung cancer screen baselin result lss previous report here report find year on screen final result lss studi total 1660 subject random ldct arm 1658 cxr arm complianc screen declin baselin year on ldct arm declin baselin year on cxr arm posit rate year on screen 25.8 ldct 8.7 cxr cancer yield significantli year on ldct 0.57 baselin 1.9 cancer yield cxr increas 0.45 baselin 0.68 year on forti lung cancer ldct arm cxr arm diagnos studi period stage cancer compris case ldct arm cxr arm total stage iii-iv cancer observ ldct arm versu nine cxr arm lss establish feasibl rct compar annual spiral chest x-rai lung cancer screen
purpos extracellular matrix ecm protein plai signific role surviv metastasi cancer cell tenascin-c tn-c extracellular matrix protein larg isoform implic tumor progress goal studi analyz express small larg isoform tn-c non-small cell lung cancer nsclc determin function signific experiment design tn-c express studi tumor non-tumor tissu patient nsclc mrna protein level immunomodulatori properti larg isoform tn-c analyz determin effect lymphocyt prolifer cytokin secret tumor-infiltr lymphocyt til result quantit real-time pcr analysi show eight-fold increas amount larg isoform cancer cell compar adjac normal tissu express protein level western blot analysi us murin monoclon anti-tn-c antibodi detect increas express larg isoform tumor tissu correl develop recurr diseas 18-fold increas express larg tn-c isoform observ patient recurr nsclc compar non-recurr nsclc larg isoform tn-c significantli inhibit anti-cd3 mitogen-induc prolifer human peripher blood lymphocyt interferon-gamma product til isol lung cancer specimen conclus increas express tn-c observ site tumor nsclc correl recurr tn-c inhibit til prolifer cytokin therebi promot tumor immun evas recurr
detect malign bronchial tree earli stage carcinoma situ ci augment cure rate consider shown sensit autofluoresc bronchoscopi better white light bronchoscopi detect ci dysplast lesion autofluoresc bronchoscopi howev character low specif high rate fals posit find present paper propos combin autofluoresc bronchoscopi optic spectroscopi improv specif autofluoresc imag maintain high sensit standard autofluoresc bronchoscopi us find suspect lesion upper bronchial tree lesion subsequ character spectroscop us custom made fiberopt probe autofluoresc spectra lesion well reflect spectra measur will show preliminari report addit spectroscop techniqu decreas rate fals posit find best result obtain both spectroscop modal combin
f-18 fluorodeoxyglucos-positron emiss tomographi pet investig patient suspect residu diseas intrathorac recurr pneumonectomi patient identifi prospect databas impact pet stage patient manag assess clinic outcom us assess appropri manag pet perform case post-oper later suspect recurr patient good perform statu extens diseas convent imag pet chang treatment case five patient pet chang treatment intent cur versu non-cur radic radiotherapi palli observ support care palli radic patient unexplain pain pet appropri show evid diseas addit five case pet influenc choic dose us concurr chemotherapi target volum patient tumour limit diseas pet favour outcom wherea extens diseas suffer earli tumour progress pet discord convent assess case pet valuabl pneumonectomi patient consid adjuv salvag radiotherapi specif reduc due post-oper inflammatori chang
sialyl lewi antigen sle x/a cancer-associ carbohydr determin serv ligand selectin famili associ hematogen metastasi cancer clinicopatholog valu sialyl lewi sle sialyl lewi sle lung cancer remain controversi us immunohistochemistri express sle sle antigen airwai mucin muc5ac protein suppos major carri protein sialyl lewi moieti studi surgic resect tumor tissu patient stage nsclc thirti-two 52.5 studi subject found posit express sle 65.6 posit express sle 26.2 posit muc5ac protein both express sle muc5ac associ adenocarcinoma subtyp patient bear tumor muc5ac sle express higher probabl post-oper distant metastasi surviv analysi demonstr patient bear tumor express sle antigen muc5ac shorter overal surviv multivari logist regress show ag year old 0.207 0.075-0.569 0.002 nodal statu 6.575 2.459-17.583 &lt 0.001 muc5ac 5.545 1.998-15.386 0.001 independ factor affect surviv conclud express sle relat muc5ac protein patient tumor co-express both muc5ac sle antigen worst surviv
background object determin prognost factor long-term survivor lt stage non-small cell lung cancer nsclc undergon variou treatment patient method 1990 1999 222 nsclc patient stage diseas treat depart review initi treatment 135 patient treat chemotherapi alon patient combin chemotherapi radiotherapi patient underw oper therapeut modal receiv radiotherapi alon result seventeen 7.7 patient surviv year on adenocarcinoma among lt eight patient receiv surgeri initi therapi 94.1 receiv type local-control therapi includ surgeri radiotherapi cours diseas regard clinic characterist lt other non-lt earli statu singl metastat site good perform statu surgeri initi therapi found significantli import factor lt multivari analysi us logist regress model show earli statu surgic treatment significantli associ lt conclus select patient earli statu appropri candid aggress multimod treatment includ surgeri order provid long-term surviv stage nsclc
background impact adjuv chemotherapi manag resect non-small cell lung cancer nsclc highli debat aim studi evalu outcom categori patient treat militari hospit bucharest surgeri institut oncolog bucharest patient method retrospect analyz surviv data accord variou patient' characterist correspond pattern relaps along data concern program result number 311 consecut treat patient pt januari 1994 octob 2002 evalu patient radic resect receiv adjuv chemotherapi plan cisplatin-base deliv six cycl addit 141 pt receiv post-oper irradi demograph sex 252 median ag rang 31-75 stage iii 140 iii median follow-up month overal median surviv consid patient month 5-year surviv rate 5-year accord stage 5-year follow stage reach/94 stage month/59 stage iii month/37 stage iii month/27 accord lymph node statu reach pn-neg pt month pn-posit pt 0.0002 5-year versu respect platinum-base deliv 295 pt medium number cycl five number relaps record distant local distant local site distant relaps bra oss pul oth conclus analysi show good long-term surviv data adjuv surgeri nsclc look compar superior commun surgeri-onli seri patholog invas lymph node strong advers effect patient' outcom posit impact set indirectli sustain pattern relaps place brain sanctuari first rank overal patient' complianc good deliv medium five cycl adjuv platinum-base
purpos phase studi assess role induct chemotherapi manag stage iiia non-small-cell lung cancer nsclc report long-term follow-up toronto phase trial method sixti five patient mediastinoscopi proven stage iiia nsclc receiv two cycl preoper mvp vlb/p follow thoracotomi follow two cours chemotherapi result overal respons rate 67.7 three complet partial respond forti seven patient went thoracotomi complet resect patholog 4.6 patient tumour remain three postop death well five chemotherapi relat death patient complet resect recur includ eight brain median surviv entir patient 18.6 month year surviv year surviv year surviv conclus long-term surviv induct chemotherapi maintain high incid brain recurr warrant assess role prophylact cranial radiat role surgeri stage iiia nsclc induct chemotherapi await studi
primari object trial determin 1-year surviv advanc non-small cell lung cancer ansclc patient year 0-2 year receiv sequenti paclitaxel carboplatin --> concurr secondari object assess toxic qualiti life total 121 patient nsclc treat p--> patient receiv paclitaxel mg/m weekli follow week rest 4-week cycl repeat relaps relaps patient receiv carboplatin auc dai 3-week cycl evid progress lack improv patient receiv paclitaxel mg/m carboplatin auc weekli follow week rest relaps patient both studi premed prior paclitaxel administr sequenti result median surviv 8.2 month rang &lt 1-18.8 patient median surviv 9.2 month rang &lt 1-22.0 both group p--> 1-year surviv patient treat sequenti treatment-relat ae trae grade includ fatigu neuropathi leukopenia diarrhea grade ae limit neutropenia febril neutropenia sepsi episod patient receiv concurr trae includ neutropenia leukopenia short breath bilater bone pain leukopenia neutropenia grade event report analysi qualiti life qol questionnair indic obviou differ treatment group studi drug treatment schema well-toler administ commun set result surviv rate similar report literatur combin therapi administ high risk patient find optim chemotherapi regimen toler remain challeng elderli patient
purpos standard treatment advanc non-small cell lung cancer nsclc consist platinum base combin chemotherapi efficaci limit treatment toxic trial evalu weekli regimen docetaxel gemcitabin advanc nsclc primari endpoint object respons rate endpoint 1-year surviv median surviv median durat respons median diseas-free progress safeti qualiti life patient method fifti patient advanc nsclc treat patient receiv docetaxel per week mg/m week 1-6 gemcitabin per week 900 mg/m week 8-week cycl repeat total three cycl patient complet qualiti life survei fact-l befor cycl result median ag 68.5 year year old intent-to-treat itt analysi respons patient partial respons five patient stabl diseas 1-year surviv median surviv patient 6.9 month rang &lt 1-26.2 median progress-free surviv 5.1 month rang &lt 1-25.5 toxic grade includ neutropenia thrombocytopenia disord nausea vomit dehydr diarrhea stomach pain asthenia patient experienc hematolog toxic grade qualiti life decreas studi conclus studi demonstr nonplatinum doublet docetaxel gemcitabin given weekli schedul advanc nsclc efficaci similar report regimen well toler non-platinum base regimen appear promis warrant evalu
gefitinib activ well toler patient advanc non-small cell lung cancer nsclc howev role patient brain metastas clearli defin conduct prospect studi give gefitinib nsclc patient irrespect perform statu number prior treatment regimen presenc brain metastas total patient enrol fifti-seven patient measur lesion object respons rate 33.3 confid interv [95 ci] 20.7-46.0 enrol patient diseas control rate 63.2 52.1-74.3 median progress-free surviv 5.0 month 3.6-6.5 month median overal surviv 9.9 month 4.9-14.8 month twenti-on patient simultan assess intracrani lesion icl extracrani lesion ecl 81.0 show compar tumor respons surviv differ patient metastat brain diseas most drug-relat advers event mild intoler toxic happen five patient four interstiti pneumonia 5.8 sever skin toxic tightli associ tumor respons patient surviv 0.007 &lt 0.001 associ consist analysi us earli toxic profil 0.033 0.001 conclus gefitinib activ patient brain metastasi nsclc tumor respons relat skin toxic feasibl conduct random trial identifi role gefitinib alon combin modal treatment nsclc patient metastat brain lesion
present case 59-year-old man small cell lung cancer sclc develop heavi thorac pain becaus spontan mediastin emphysema autopsi document mucos lesion posterior tracheal wall air leak mediastinum occurr spontan mediastin emphysema patient small cell lung cancer rare describ literatur
diseas-direct treatment lung cancer reduc morbid extend life patient howev provid recogn treat symptom diseas import treatment diseas particularli true advanc diseas diseas-direct therapi exhaust aggress assess symptom us palli therapi significantli reduc symptomatolog advanc lung cancer impact symptom pain dyspnea cachexia well known tend under-treat addit simpl maneuv opiat rotat pain relief underutil diagnosi lung cancer associ symptom result sever psychosoci stress patient exacerb symptom viciou cycl understand cope strategi aid medic provid assist patient ill
small cell lung cancer sclc highli sensit chemotherapi radiotherapi howev despit initi respons relaps common most patient eventu succumb diseas patient limit-diseas sclc repres approxim patient sclc potenti curabl treat combin chemotherapi thorac radiotherapi trt chemotherapi consist four cycl combin cisplatin etoposid thorac radiotherapi start first second cycl chemotherapi prefer administ twice daili week prophylact cranial irradi pci recommend patient achiev complet respons surgeri limit valu sclc except patient present solitari pulmonari nodul approxim patient limit diseas -sclc cure aggress approach newer treatment modal current under investig
gefitinib small molecul specif inhibit tyrosin kinas activ epiderm growth factor receptor egfr type interf adenosin triphosph atp bind site dose maxim inhibit egfr tyrosin kinas activ chosen phase trial most common side effect gefitinib low-grade rash diarrhea infrequ seriou side effect gefitinib interstiti lung diseas ild iressa dose evalu advanc lung cancer phase trial ideal ideal singl agent gefitinib 250 500 oral per dai pretreat patient non-small cell lung cancer nsclc found patient ideal-1 patient ideal-2 major object respons improv symptom data ideal trial extens experi 000 patient treat expand access program suggest patient major object respons probabl signific surviv benefit addit palli benefit addit approxim patient ideal trial experienc improv symptom gefitinib approv third line treatment nsclc gefitinib effect safe well-toler singl-agent therapi previous treat nsclc direct comparison small molecul inhibitor egfr gefitinib erlotinib appear similar efficaci erlotinib shown produc surviv advantag compar best support care unselect group previous treat patient nsclc similar trial complet compar gefitinib best support care similar surviv advantag gefitinib nonsmok women patient adenocarcinoma like major object respons patient bronchioalveolar lung cancer subtyp nsclc like respond gefitinib sever group report most tumor experienc major object respons gefitinib mutat associ atp-bind site egfr reason move gefitinib second-line therapi patient known tumor like respond gefitinib treat patient gefitinib first-line therapi appropri clinic trial approv institut review board irb outsid clinic trial patient advanc diseas initi treat combin doublet chemotherapi strong evid benefit concurr chemotherapi gefitinib gefitinib given concurr cytotox chemotherapi initi treatment nsclc sequenti therapi combin chemotherapi gefitinib advanc diseas adjuv therapi done context clinic trial approv irb preclin evid suggest gefitinib radiosensit earli result trial combin radiat chemoradiotherapi gefitinib shown combin excess addit toxic proven clinic benefit concurr gefitinib radiat gefitinib given radiat part appropri clinic trial approv irb
non-small cell lung cancer nsclc lead caus cancer-relat death unit state chemotherapi shown increas surviv patient advanc-stage diseas surviv benefit modest cost signific toxic treatment option second-line set limit pemetrex multitarget antifol activ singl agent part combin chemotherapi nsclc report recent phase iii clinic trial surviv outcom second-line set patient treat pemetrex docetaxel similar importantli major toxic us pemetrex vitamin folat supplement docetaxel base singl agent activ eas administr favor toxic profil pemetrex potenti incorpor variou set nsclc includ metastat diseas adjuv therapi local advanc diseas
p53 uniqu dna bind protein two distinct dna bind domain central domain sequenc-specif dna bind c-termin basic dna bind domain domain structur-specif dna bind contrast appar inhibitori effect domain p53 bind sequenc-specif dna vitro here demonstr domain enhanc p53 bind endogen p21 waf1 promot mediat rapid transactiv p21 waf1 paradox resolv observ domain requir rapid bind non-sequenc-specif genom dna ns-dna evid global chromatin immunoprecipit analysi p53 dna bind vivo find provid first vivo evid eukaryot system support bind ns-dna intermedi step search specif site propos von hippel berg furthermor specul bind structur-specif dna domain mechan p53 rapid bind genom dna free state facilit search target site genom undergo genotox stress
farnesyltransferas inhibitor fti demonstr induc growth arrest apoptosi independ ra mutat altern akt propos potenti target fti's action studi investig whether lonafarnib effect inhibit growth human nonsmal cell lung cancer nsclc cell elucid role akt mediat growth inhibitori effect lonafarnib clinic achiev concentr rang effect inhibit growth nsclc cell line particularli prolong treatment regardless ra mutat statu lonafarnib arrest cell growth phase major test cell line howev induc apoptosi cell cultur low serum 0.1 medium major nsclc cell line express undetect level phosphoryl akt p-akt lonafarnib mum decreas total akt level p-akt level test cell line treatment unexpectedli lonafarnib increas p-akt level on cell line sensit other lonafarnib treatment underw arrest bovin serum albumin complet rescu cell lonafarnib-induc apoptosi low serum medium indic protein rather cytokin growth factor serum mask lonafarnib's pro-apoptot effect conclud lonafarnib effect inhibit growth nsclc cell via growth arrest induct apoptosi downregul akt
purpos patient bone metastas lung cancer experi skelet-relat event sre includ patholog fractur spinal cord compress hypercalcemia pain requir surgeri radiotherapi opioid analges complic result impair mobil reduc qualiti life signific neg impact surviv econom consequ sre patient lung cancer examin method conduct retrospect analysi us larg health insur claim databas estim incid cost treatment sre patient bone metastas lung cancer treat naturalist set studi subject encount diagnosi primari lung cancer encount diagnosi metastas bone sre identifi base occurr date first diagnosi bone metastas encount diagnosi patholog fractur spinal cord compress hypercalcemia bone surgeri radiotherapi procedur initi opioid analges therapi surviv cost sre-relat care patient sre estim us kaplan-meier method result identifi 534 patient lung cancer bone metastas includ 295 sre radiotherapi fractur most common sre median surviv first identifi sre 4.1 month confid interv 3.6-5.5 month estim lifetim sre-relat cost per patient usd 979 confid interv usd 193-13 766 radiotherapi account greatest proport cost sre type conclus econom burden sre patient bone metastas lung cancer substanti intraven bisphosphon zoledron acid shown prevent event reduc cost
object cell densiti cultur cell demonstr sever alter natur cell kinet chang metastat aggress cancer line under differ cell densiti yet studi method current studi investig influenc chang cell densiti cultur cancer cell colon b16-f10 inject tail vein balb/c mice metastat activ evalu number lung metastas possibl mechan phenomenon discuss base basi result invas assai cell adhes assai result number metastat nodul significantli higher high-densiti group low on colon &lt 0.005 howev phenomenon b16-f10 perform same experi chang environ opposit condit cell low- high-densiti group result show metastat activ higher high-densiti group moreov differ regard invas activ high- low-densiti group adhes assai show differ adhes cell rate significantli higher high-densiti group especi earli period cocultur human umbil vein endotheli cell huvec &lt 0.05 conclus cell type metastat activ alter revers chang environ cell densiti rel short period result epigenet chang cancer cell suggest plai certain role malign potenti
rasayana group herbal formul us improv health bodi recent studi demonstr immunostimulatori antioxid activ rasayana us tumor regress object studi evalu brahma rasayana inhibit tumor develop prevent metastasi vivo us copenhagen rat mat-lylu cell model system copenhagen rat inject mat-lylu cell treat brahma rasayana onc daili treatment follow second dai cell inocul experi studi compris comparison surviv time bodi weight tumor incid tumor size tumor weight histopatholog examin lung metastasi serum testosteron level rasayana treat control anim brahma rasayana treatment result 25-37 decreas palpabl tumor incid delai 1-2 week tumor occurr lower mean tumor volum much 14-35 signific reduct tumor weight lung metastasi comparison untreat control ayurved poli herbal prepar brahma rasayana plai benefici role prevent tumor incid tumor growth metastat spread inexpens prepar littl advers side effect potenti lead chemoprevent compound prove us treatment disord human prostat cancer
concurr deliveri chemotherapi radiotherapi synergist effect tumor control improv median overal surviv patient local advanc non-small cell lung cancer appreci acut late morbid occur esophagu lung treatment acut radiat esophag pulmonari toxic emerg evid suggest volum normal lung expos certain threshold dose predict incid pneumon clinic data indic amifostin ethyol medimmun inc gaithersburg organ thiophosph act select cytoprotect agent normal tissu toxic chemotherapi moreov preclin clinic data suggest subcutan administr amifostin better toler similar efficaci intraven rout conduct open-label trial accru patient local advanc non-small cell lung cancer will receiv concurr chemoradiotherapi cisplatin/etoposid carboplatin/paclitaxel plu deliv us 3-dimension conform radiotherapi treatment plan amifostin 500 befor incid sever acut radiat esophag acut radiat pneumon chronic radiat pneumon chang pulmonari function will record will element treatment plan dose volum histogram data lung esophagu pre- post-therapi pulmonari function primari endpoint other includ gener safeti assess subcutan amifostin administr
concurr chemoradiotherapi standard treatment good-perform patient non-small cell lung cancer acut esophag frequent toxic incid sever acut esophag grade patient treat standard onc-daili radiat therapi alon 1.3 increas addit concurr chemotherapi combin hyperfraction twice-daili radiat therapi plu concomit chemotherapi esophag almost caus mortal result signific morbid forc treatment break associ inferior outcom non-small cell lung cancer substanti investig effort prevent amelior esophag conduct describ herein rational/studi design multi-institut phase random studi evalu daili subcutan intraven bolu infus amifostin patient non-small cell lung cancer receiv standard fraction thorac radiat therapi concurr weekli paclitaxel carboplatin chemotherapi
concurr chemoradi probabl plu system chemotherapi current offer best treatment strategi stage iiia/iiib non-small cell lung cancer howev approach control local diseas well becaus inadequ radiat dose few studi explor higher standard radiat dose major fear higher dose increas patient morbid improv cure rate univers north carolina chapel hill phase i/ii trial suggest least given safe patient cytotox drug suggest improv surviv moreov trial data suggest cytoprotect radioprotect agent amifostin us reduc esophag possibl pneumon patient treat convent radiat dose describ herein propos clinic trial design test hypothesi higher radiat dose lead surviv advantag patient non-small cell lung cancer valu amifostin cytoprotect agent high-radiat dose rang
evid import maintain full dose schedul chemotherapi lung cancer vari consider histolog type sever studi evalu chemotherapi dose dose intens small cell lung cancer fewer studi evalu import chemotherapi non-small cell lung cancer current guidelin nation comprehens cancer network recommend adjuv chemotherapi most patient resect diseas increas evid chemotherapi benefit elderli patient much younger patient clinic trial set palli treatment advanc non-small cell lung cancer focus test regimen rather evalu impact maintain dose schedul standard chemotherapi regimen howev light potenti cur role chemotherapi adjuv set optim dose schedul regimen import impact outcom addit data suggest respons neoadjuv set correl surviv appropri set test effect chemotherapi dose schedul surviv primari measur treatment efficaci point qualiti life diseas stabil consid advanc diseas becaus regimen will shape choic treatment adjuv neoadjuv set import determin signific maintain full dose schedul convent chemotherapi regimen ensur optim outcom treatment lung cancer
on unresolv design issu clinic trial qualiti life qol endpoint frequenc measur patient stage iii lung cancer retrospect review clinic trial qol interv vari wide week treatment follow-up interv gener month purpos methodolog studi determin appropri interv qol serial measur base prospect collect data patient studi part phase i/i studi us combin chemotherapi patient advanc non-small cell lung cancer nsclc typic patient lung cancer clinic trial median ag interquartil rang year major male baselin median karnofski perform statu interquartil rang primari instrument develop 1985 lung cancer symptom scale lcss patient form 9-item self-report site-specif qol measur method outcom implic find research present establish method obtain appropri serial measur interv qol therapi clinic trial base find studi everi 3-week qol assess patient advanc nsclc provid data similar frequent evalu data preserv compar twice-weekli assess confid interv 86-98 0.05 frequent assess everi everi week retain data recommend minimum adequaci rate retain high percentag qol inform lessen effect measur bia due patient attrit give valid qol studi
object explor carcinogen activ sterigmatocystin possibl synergist carcinogen effect deoxynivalenol don nih mice method nih mice randomli divid group five group mice given gastric intub microg/kg microg/kg microg/kg don 1.5 microg/kg microg/kg don 1.5 microg/kg don 1.5 microg/kg respect time week week remain group mice given normal salin serv control mice fed hplc-confirm mycotoxin-free food analysi mice kill patholog examin 58th 74th week result patholog chang found control group mice adenocarcinoma lung observ 25.0 41.7 62.5 69.2 37.5 mice given microg/kg microg/kg microg/kg don 1.5 microg/kg microg/kg don 1.5 microg/kg don 1.5 microg/kg respect addit dysplasia glandular stomach detect 50.0 58.3 37.5 53.8 25.0 mice similarli treat conclus oral administr don induc adenocarcinoma lung dysplasia glandular stomach nih mice synergist carcinogen effect both don given
object investig chang biolog properti non-small-cell lung cancer nsclc a549 cell egf receptor egfr express suppress short interfer rna sirna method a549 cell transfect synthet egfr sequenc-specif sirna lipofectamin egfr express examin western blot flow cytometri biolog featur transfect a549 cell assess cell cycl analysi coloni format chemosensit assai result sequenc-specif sirna target egfr significantli down-regul express a549 cell cell growth coloni format inhibit 85.0 63.3 respect compar non-sequenc-specif sirna treat cell decreas egfr express accompani 12.7 increas a549 cell phase 6.6 decreas s-phase egfr sequenc-specif sirna transfect a549 cell much sensit cytotox effect cisplatin 77.2 decreas compar non-sequenc-specif irna transfect a540 cell conclus down regul egfr express nsclc sequenc-specif sirna consid addit option treatment egfr over-express cancer includ nsclc
object evalu growth inhibitori effect adriamycin adm conjug anti-lung cancer singl-chain antibodi scfv 2a7-1 lung adenocarcinoma cell line vitro method 2a7-1 cell cultur medium concentr ultra-filtrat amicon p10z filter solubl scfv purifi us rpa purif kit adm conjug 2a7-1 glutaraldehyd 280 490 conjug 2a7-1-adm determin spectrophotometri molar ratio 2a7-1 adm calcul immunoreact conjug detect immunohistochemistri growth inhibitori effect lung adenocarcinoma cell line determin coloni format assai vitro result molar ratio 2a7-1 adm 3.2 conjug strongli react cell growth inhibitori effect cell time potent adm conclus adriamycin conjug anti-lung cancer singl-chain antibodi 2a7-1 much higher cytotox activ unconjug adriamycin human lung adenocarcinoma
object investig effect ginsenosid-rg3 lung metastasi ribonucleas inhibitor gene-transfect mous b16 melanoma method c57bl/6 mice inject parent ri-transfect b16 melanoma cell lung metastasi assess number surfac tumor nodul mice divid group group iii mice given parent mock-transfect ri-transfect b16 melanoma cell respect group rg3 1.5 mg/kg q.o.d given mice bear parent mock-transfect ri-transfect b16 melanoma respect micovessel densiti mvd lung metastat tumor assess immunohistochem stain factor viii-r express result number tumor nodul significantli decreas mice inject ri-transfect b16 melanoma iii compar rg3 treatment per decreas number lung tumor nodul lesser extent compar iii howev rg3 synerg transfect result most signific inhibit lung metastasi mice di dai experi wherea mice aliv observ period on on half month mvd significantli decreas lung tumor nodul mice inject ri-transfect b16 melanoma decreas addit rg3 given conclus transfect ribonucleas inhibitor gene significantli reduc metastat potenti b16 melanoma ginsenosid-rg3 synergist effect
object evalu antitumor efficaci time tumor progress ttp toxic iressa zd1839 select epiderm growth factor receptor tyrosin kinas inhibitor advanc non-small-cell lung cancer nsclc patient fail respond previou chemotherapi method fifti-two patient grade nsclc previous treat chemotherapi 77.0 patient second line therapi receiv 250 iressa oral onc daili diseas progress develop intoler toxic reaction requir receiv tumor-evalu befor treatment on month iressa administr everi month thereaft result complet regress observ partial respons rate 21.2 11/52 stabl diseas 32.7 17/52 diseas control rate 53.8 progress diseas 46.2 24/52 median time tumor progress ttp 3.5 month among patient follow on year 1-year surviv rate 31.8 symptomat improv rate 52.9 most common advers effect skin reaction diarrhea gener mild grade on patient withdrew trial becaus grade iii hepat toxic increas alt ast conclus iressa signific antitumor activ advanc nsclc patient previous fail second third line chemotherapi greatli allevi tumor relat symptom advers effect gener toler iressa suitabl patient poor perform statu ecog
object evalu short-term therapeut effect side effect combin hydroxycamptothecin oxaliplatin treatment advanc digest tract cancer method thirti patient suffer advanc digest tract tumor includ gastric cancer colorect cancer cholecyst cancer malign fibroadenoma studi treat hydroxycamptothecin plu oxaliplatin cycl interv dai result complet respons partial respons stabl diseas progress diseas rate 3.3 1/30 36.7 11/30 53.3 15/30 6.7 3/30 respect overal respons rate 40.0 12/30 whole cycl leukocytopenia observ cycl 44.2 cycl 55.9 grade iii diarrhea develop cycl 54.5 cycl 47.6 grade iii side effect fever alopecia nausea vomit constip hepat renal function abnorm neuriti conclus satisfactori respons rate obtain advanc colorect cancer treat hydroxycamptothecin plu oxaliplatin toxic consist sever leukocytopenia diarrhea
object paclitaxel us phase trial combin cisplatin esophag cancer anti-tumor respons toxic surviv treat patient evalu method thirti patient advanc unresect complic metastasi allot twenti-seven patient prior chemotherapi patient receiv adjuv chemotherapi patient given paclitaxel 175 mg/m 3-hour infus cisplatin mg/m daili granulocyt coloni-stimul factor g-csf routin administ patient neutropenia treatment recycl everi dai result thirti patient male/femal 28/2 median ag complet median cycl patient evalu respons major object respons observ patient 59.3 confid interv 38.9 75.5 includ complet respons 18.5 partial respons 40.7 median time tumor progress 5.0 month rang month median actuari surviv 9.7 month rang month twenti-eight patient assess toxic most common nonhematolog toxic alopecia grade neutropenia observ 17.9 patient toxic manag dose attenu g-csf support conclus combin paclitaxel cisplatin consid main regimen treatment advanc esophag cancer
background cyclooxygenas cox overexpress sever tumor entiti seem plai kei role carcinogenesi make potenti target cancer therapi materi method twelv phosphorothio-modifi antisens oligonucleotid asodn six target cox-2 mrna transfect a-549 lung carcinoma cell cox-2 mrna protein level determin quantit rt-pcr flow cytometri respect cell growth assess measur alamar blue reduct result test asodn exhibit rang activ most potent asodn reduc uninduc cox-2 mrna protein level respect asodn influenc cell growth growth reduct observ transfect anoth asodn suppress cox-2 mrna protein level conclus us asodn direct cox-2 mrna promis approach inhibit cox-2 express tumor cell
clinic studi report irinotecan reproduc antitumor activ lung cancer both cisplatin sn-38 kei drug treatment lung cancer combin on most promis regimen avail us lung cancer cell line abc-1 sbc-3 examin cytotox effect schedul well effect cisplatin topoisomeras activ cytotox determin mtt assai abc-1 sbc-3 cell incub variou concentr both drug 96-well micropl hour humidifi co2 atmospher degre synerg evalu median-effect plot analysi combin index isobologram method chou talalai abc-1 sbc-3 cell expos 10/microm cisplatin on hour topoisomeras activ determin supercoil-dna relax assai synerg observ abc-1 sbc-3 cell cisplatin given first follow sn-38 7-ethyl-10-hydroxycamptothecin cisplatin topoisomeras activ decreas 1-2 hour exposur cisplatin recov gradual 4-5 hour cisplatin exposur both abc-1 sbc-3 cell pretreat cisplatin will impact sensit sn-38
focal adhes kinas fak non-receptor tyrosin kinas local point cell contact extracellular matrix call focal adhes factor induc tyrosin phosphoryl fak includ growth factor neuropeptid integrin-depend adhes extracellular matrix fak implic sever cellular process invas motil prolifer apoptosi addit fak express shown elev number differ human cancer suggest role develop malign examin biolog function fak us small inhibitori rna sirna cancer cell fak sirna reduc fak protein level approxim sever cancer cell line clear evid apoptosi howev clonogen soft-agar assai h1299 lung cancer cell line fak sirna treatment led decreas coloni format furthermor fak sirna-treat cell displai decreas migrat serum egf epiderm growth factor us chemo-attract result demonstr inhibit fak protein lead alter cell growth migrat
irinotecan on most activ drug us treatment small cell lung cancer sclc 7-ethyl-10-hydroxi-camptothecin sn-38 activ metabolit irinotecan establish sn-38-resist sublin sbc-3/sn-38 continu exposur sn-38 human sclc cell line sbc-3 us 3-[4 5-dimethyl-thiazol-2-yl] 5-diphenyltetrazolium bromid assai evalu cytotox anticanc agent sbc-3/sn-38 cell 73-fold resist parent sbc-3 cell sn-38 show cross-resist topoisomeras topo inhibitor irinotecan topotecan topo inhibitor adriamycin etoposid antimicrotubul agent vincristin vindesin vinorelbin docetaxel alkyl agent cyclophosphamid ifosfamid platinum cisplatin carboplatin antifol methotrex interestingli resist sublin reserv sensit bleomycin 5-fluorouracil sbc-3/sn-38 cell decreas topo activ compar parent cell sn-38-resist cell line sbc-3/sn-38 will us elucid mechan action topo inhibitor
background previous shown abil bacteriophag substrain hap1 select higher affin melanoma cell reveal antimetastat activ mous melanoma model here investig potenti phage anticanc activ primari tumour model materi method mice inocul subcutan b16 llc cell collect vitro cultur bacteriophag hap1 inject intraperiton daili pfu/mous except experi concern dose-depend result treatment purifi prepar bacteriophag result signific reduct tumour size effect dose-depend hap1 effect activ dose-depend parallel experi non-purifi bacteriophag lysat result signific stimul tumour growth conclus data suggest purifi bacteriophag inhibit tumour growth phenomenon potenti import clinic implic oncolog
aim studi investig earli effect transplatin stereo-isom cisplatin oncogen inbr cba/ca mice cisplatin commonli us treatment squamou cell carcinoma head neck cisplatin strong oncogen activ effect compar structur analogu transplatin bodi weight equival amount human dose transplatin administ intra-periton 8-week-old inbr femal cba/ca mice twenti-four hour treatment rna isol target organ express c-myc ha-ra p53 gene examin investig earli chang show signific overexpress compar cisplatin signific effect oncogen express short-term vivo test system
background beta-defensin hbd express lung epitheli cell act antimicrobi agent most lung cancer origin pulmonari epitheli cell produc hbd materi method measur serum hbd-1 hbd-2 level healthi subject patient lung cancer patient pneumonia radioimmunoassai result serum hbd-1 level higher patient lung cancer patient pneumonia serum hbd-2 level higher patient lung cancer cut-off valu posit hbd-1 set mean 2sd sensit specif hbd-1 whole group patient lung cancer 76.4 94.0 respect proport patient hbd-1-posit lung cancer clinic stage 69.2 conclus serum hbd level high patient lung cancer serum hbd-1 level us auxiliari diagnost tool lung cancer
report here vivo visual cancer cell interact us stabl sublin green fluoresc protein gfp red fluoresc protein rfp -express ht-1080 human fibrosarcoma cell color-code fibrosarcoma cell line show similar cell prolifer lung metastasi potenti color-code cell mix ratio inject tail vein sever combin immunodefici scid mice result experiment lung metastas simultan imag ratio determin color-pixel analysi fluoresc color code cancer cell enabl visual interact cancer cell us distinguish cancer cell genotyp phenotyp
carcinoid tumor recogn low-grade malign recurr bronchopulmonari typic carcinoid extrem rare herein report case recurr multipl intralumin bronchial typic carcinoid successfulli remov us argon plasma coagul bronchoscop approach 48-year-old man undergon resect pulmonari typic carcinoid year previous suffer product cough hemosputum month bronchoscop examin reveal multipl intralumin bronchial polypoid tumor base histopatholog find diagnos recurr typic carcinoid patient underw argon plasma coagul apc treatment bronchoscop approach sever time apc treatment consid safer method convent bronchoscop treatment neodymium-yttrium aluminum garnet nd-yag laser electrocauteri seri treatment symptom complet improv recurr found month follow-up
evalu possibl role cystein proteas serin proteas well respect inhibitor receptor prognost factor nsclc examin first time biolog paramet relat three proteolyt system homogen collect 147 case nsclc activ cath cath a7.5 protein level cath cath upa pai-1 upar [measur three differ assai upar adi upar hd13 upar iiif10 measur homogen lung tumour tissu correspond non-malign lung parenchyma total cath activ cath enzymat activ fraction cath stabl activ 7.5 cath a7.5 determin fluorogen assai us synthet substrat z-arg-arg-amc concentr cath cath upa pai-1 upar determin elisa upar determin us three differ elisa format median level cath 5.1-fold cath a7.5 2.5-fold cath 8.5-fold cath 6.6-fold upa 6.5-fold pai-1 4.2-fold upar adi 2.2-fold upar hd13 4.0-fold upar iiif10 2.6-fold higher tumour tissu compar lung parenchyma cath cath a7.5 cath primari tumour correl lymph node metastas regard histolog concentr pai-1 seem associ histolog cell type nsclc found highest valu pai-1 larg cell carcinoma scc carcinoid lowest valu metastas primari tumour organ pai-1 significantli increas poorli-differenti cell compar well- moder- differenti cell g1/g2 pai-1 significantli correl cath cath a7.5 upar adi upar hd13 upar iiif10 upa weakli cath cath signific correl overal surviv total popul nsclc patient observ univari analysi cath cath pai-1 upar adi upar hd13 upar iiif10 cath significantli associ poor prognosi regard histolog tumour type patient squamou cell carcinoma cath a7.5 pai-1 remain signific prognost factor multivari surviv analysi two proteolyt factor pai-1 upar iii101f stai signific conclus among biolog paramet evalu same cohort patient pai-1 upar adi upar hd13 upar iiif10 cath cath prognost factor overal surviv nsclc patient moreov pai-1 upar iiif10 add independ prognost inform regard establish clinic histomorpholog factor nsclc
background explor express fatti acid synthas fa lung carcinoma associ clinico-patholog featur prognosi fa recent discov molecul involv energi suppli normal cell fa overexpress neoplast tissu becaus increas necess energi patient method on hundr six patient non-small cell lung carcinoma follow-up averag period year fa express detect immunohistochem result fa stain observ 106 case 57.54 statist analysi reveal fa overal low prognost valu 0.14 fa-neg express stage patient show trend better surviv 0.10 ptnm stage &lt 0.0001 signific prognost marker overal surviv conclus fa reliabl marker low-stage clinic aggress lung carcinoma determin fa express lung carcinoma stratifi patient determin therapeut approach care
background studi design confirm activ cisplatin/vinorelbin c/v combin non-small cell lung carcinoma nsclc patient method treatment consist vinorelbin i.v slow infus mg/m2 everi week cisplatin 120 mg/m2 dai everi week treatment continu complet 22-week treatment plan diseas progress persist toxic patient refus result seventi-five patient enter studi median ag year major cell type adeno- squamou larg cell carcinoma nineteen patient receiv suboptim treatment cours vinorelbin median cours c/v rang 0-4 rang 0-22 respect both drug median dose-intens project toxic gener accept mainli hematolog life-threaten thirti-five patient respond complet respons overal respons rate 46.7 estim median time progress week quartil rang 13-46 median surviv week quartil rage 17-108 conclus c/v combin fairli well toler decidedli activ associ prolong surviv
evalu relationship cell prolifer apoptosi progress lung carcinoma immunohistochemistri prolifer cell nuclear antigen pcna situ label tunel method identifi apoptot bodi perform paraffin section 135 lung carcinoma result correl correspond tumor volum model diseas progress lung tumor found increas tumor volum prolifer rate decreas significantli wherea apoptot rate increas relationship apoptot prolif indic except carcinoma tumor volum 100 cm3 data suggest progress lung carcinoma i.e increas tumor volum accompani increas apoptosi rather increas cell prolifer
background loss heterozygos loh select region chromosom 17p non-small cell lung cancer nsclc associ abnorm major clinic paramet prognosi studi materi method studi group includ consecut primari nsclc tumour four microsatellit marker chromosom three marker 17p analyz result loh least on locu found analyz tumour most frequent delet found locu d3s1481 3p14.2 sequenc delet d17s520 17p12 tp53 17p13.1 occur tumour loh occurr 17p frequent squamou cell carcinoma compar adenocarcinoma differ signific conclus signific associ found loh analyz loci tumour stage tnm grade correl loh surviv
purpos studi retrospect evalu effect fraction stereotact radiotherapi fsrt patient present intracrani metastas initi symptom lung carcinoma fifteen patient three fewer brain metastas lung carcinoma underw fsrt receiv fraction fraction april 1999 octob 2002 patient develop lesion retreat fsrt whole brain radiotherapi wbrt tumor control obtain patient median period 21.0 month rang month salvag radiotherapi whenev requir none di brain metastasi median surviv time 7.0+/-3.0 month 21.0+/-1.0 month patient extracrani metastas respect p&lt 0.01 receiv treatment primari mediastin lymph node 22.0+/-1.4 month surviv longer 8.0+/-2.5 month p&lt 0.001 overal high local control high surviv rate patient suggest fsrt appear effect safe treatment patient present intracrani metastas initi symptom lung carcinoma treatment intracrani metastas therapi primari appear improv surviv rate
object evalu associ genet polymorph glutathion s-transferas gstm1 gstt1 smoke suscept colorect cancer method case-control studi 126 patient 343 healthi control conduct investig role gstm1 gstt1 polymorph colorect cancer genotyp gstm1 gstt1 polymorph analyz multiplex allel-specif polymeras chain reaction pcr result frequenc gstm1 null gstt1 null genotyp 55.5 20.4 respect adjust ag sex among gstt1 null genotyp gstm1 null genotyp signific increas risk rectal cancer compar gstm1 non-null genotyp 9.74 1.13 83.85 2.22-fold risk colon cancer associ gstm1 null genotyp compar gstm1 non-null genotyp among current smoker 0.05 individu gstt1 null genotyp current smoke signific risk colon cancer 4.55 1.14 18.17 rectal cancer 4.60 1.11 19.11 conclus studi suggest certain null gstm1 gstt1 genotyp associ elev risk colorect cancer modifi interact two genet polymorph cigarett smoke
object identifi molecular marker lung squamou cell carcinoma cdna microarrai techniqu method cdna express profil examin microarrai surgic specimen stage lung squamou cell carcinoma gene up-regul down-regul everi specimen studi identifi express level nm23 brca2 squamou cell carcinoma lung examin immunohistochem techniqu result total 107 gene identifi up-regul down-regul six specimen immunohistochem stain show compar normal lung tissu intens nm23 express squamou cell carcinoma lung significantli increas brca-2 decreas conclus cdna microarrai us identifi gene express profil lung cancer us marker lung squamou cell carcinoma
object investig clinic valu 18f-fluorodeoxyglucos positron emiss tomographi fdg pet /ct diagnosi manag lung nodul method twenti patient evalu suspect cancer confirm cancer pet/ct scan perform discoveri ls-pet/ct system result diagnost accuraci pet/ct 100 patient patient suspect cancer diagnos have benign diseas malign patient confirm cancer fdg posit singl lesion posit pet/ct imag posit imag diagnos have metastasi tissu outsid lung metastat pet/ct scan therapi scheme patient chang continu observ practic treat anti-inflamm regimen oper local radiotherapi chemotherapi radiotherapi plu chemotherapi oper radiotherapist made us pet/ct fusion imag posit patient indic radiotherapi on receiv mm50 on cours intens medul conform radiotherapi re-examin pet/ct on half month former parenchym nodul disappear glucos metabol return normal two final oper surgeon decid oper approach estim extent lesion pet/ct fusion imag patholog result show cancer cell involv specimen margin local lymph node conclus pet/ct better discrimin malign benign lung nodul pet/ct scan facilit accur assess respons clinic stage neoadjuv therapi scheme lung cancer pet/ct fusion imag provid accur biolog target radiotherapi confirm oper plan extent surgeri
object analyz larg cohort patient rectal cancer cancer center determin prognost factor univari multivari analys method total 952 patient rectal cancer treat surgic period year oper carri 741 patient 77.8 patient 7.9 136 patient 14.3 respect mile oper 53.5 lower abdomin resect lar 33.7 result oper mortal 0.3 418 patient dead 108 month postop due recurr metastas liver lung bone patient overal mean surviv time patient 73.52 +/- 1.70 month overal 5-and 10-year surviv rate 67.6 55.4 38.2 overal 10-year surviv rate patient treat radic oper 81.4 70.3 48.8 respect kaplan-meier estim show patient gender ag radic resect histolog type liver pulmonari metastasi tnm stage predictor surviv multivari analysi show statist signific correl radic oper histolog type depth tumor invas lymphat invas tnm stage liver pulmonari metastasi conclus surviv statist signific differ among prognost factor relat radic resect lymphat invas tnm stage depth tumor invas histolog type liver pulmonari metastasi found
object investig differ prognost factor young old lung cancer patient treat chemo-radiotherapi method clinic data collect young patient &lt year old studi group randomli select old patient year old control group treat chemo-radiotherapi surviv analysi done kaplan-meier method univari analysi log rank test multivari analysi cox proport hazard model respect result median surviv time month studi group month control group 2-year surviv rate 11.1 versu 23.1 5-year surviv 3.1 versu 5.4 respect univari analys demonstr symptom durat time mi-diagnosi durat time clinic stage chemo-radiat regimen radiat dose ddp dose weight loss karnofski perform statu associ prognosi studi group symptom durat time clinic stage radiat dose ddp dose weight loss karnofski perform statu associ control group multivari analys show clinic stage weight loss karnofski perform statu independ prognost factor both group ddp dose studi group conclus overal surviv similar young old patient group differ prognost factor two group ddp dose independ prognost factor young lung cancer patient bear dose-respons relationship
object evalu possibl interact dietari intak crucifer veget glutathion s-transferas theta gstm1 gstt1 genotyp lung cancer risk method hospit-base case-control studi 716 caucasian lung cancer case 939 spous friend control conduct boston massachussett 1992 2000 dietari intak collect through food frequenc questionnair blood obtain genotyp logist regress model adjust ag gender total calori smoke variabl result higher intak crucifer veget reduc lung cancer risk among gstm1 present individu odd ratio highest versu lowest tertil 0.61 confid interv 0.39-0.95 among gstm1 null individu highest versu lowest tertil 1.15 0.78-1.68 observ statist signific interact gstm1 crucifer veget intak overal likelihood ratio test lrt 0.05 among current smoker lrt 0.01 signific interact observ gstt1 combin gstm1/t1 genotyp conclus studi higher crucifer veget intak reduc lung cancer risk among individu gstm1 present genotyp find differ prior studi specif assess isothiocyan found crucifer veget evalu asian studi popul higher level crucifer veget consumpt
object studi effect matern smoke pregnanc develop brain tumor offspr gener found increas risk most mainli reli retrospect exposur assess conduct prospect studi larg birth cohort sweden method women give birth 1983-1997 classifi smoker non-smoker base inform ascertain first prenat visit record swedish birth regist follow-up brain tumor incid among offspr through 1997 achiev linkag swedish cancer regist hazard ratio estim us cox proport hazard regress adjust demograph characterist avail birth regist result brain tumor 480 occur rate 4.5 case per 100 000 person-year children women smoke pregnanc increas incid brain tumor hazard ratio 1.24 confid interv 1.01-1.53 increas risk similar benign malign tumor most appar astrocytoma effect smoke occurr brain tumor most strongli among 2-4 year-old children conclus result support role matern smoke pregnanc etiolog childhood brain tumor find confirm prospect studi
object enterolacton phytoestrogen produc intestin microflora precursor plant food postul protect hormon-depend cancer studi associ plasma enterolacton risk prostat cancer method northern sweden health diseas cohort enterolacton concentr measur time-resolv fluoroimmunoassai plasma taken 265 men diagnos prostat cancer mean time year blood collect plasma 525 control men match ag date blood collect result signific associ quartil plasma enterolacton risk prostat cancer odd ratio prostat cancer estim condit logist regress increas concentr enterolacton quartil 1.00 refer 0.81 confid interv 0.52-1.27 1.03 0.67-1.58 1.22 0.80-1.86 adjust bodi mass index bmi smoke statu stratif ag lag time storag time tumour characterist materi alter risk estim men low enterolacton level howev significantli higher risk prostat cancer odd ratio bottom decil versu decil 1.68 1.03-2.74 conclus result support hypothesi enterolacton form dietari lignan protect prostat cancer
caveolin express downregul variou cancer cell line interestingli sever drug-resist cancer cell strong induct caveolin express report suggest role caveolin acquisit mainten multidrug resist phenotyp addit report p-glycoprotein local caveolin-rich membran domain cell studi progress expos a549 lung adenocarcinoma cell increas dose etoposid both cell line greatli increas level p-glycoprotein express mrp express level moder increas cell rais caveolin level compar control a549 cell both caveolin-1 p-glycoprotein coloc triton-insolubl membran domain cell line caveolin-1 solubil addit octylglucosid suggest two protein locat differ membran domain us anti-caveolin-1 antibodi succe immunoprecipit p-glycoprotein interestingli total cellular cholesterol major lipid compon caveola triton-insolubl domain greatli increas both cell line compar naiv a549 cell
lung cancer on lead caus cancer death worldwid poor patient prognosi larg attribut lack effect earli detect method base concept protein peptid eman tumor serum present studi aim investig serum protein pattern assess gradient polyacrylamid gel capabl discrimin lung cancer patient healthi donor addition group patient healthi donor investig western-blot apoptosi metastasi-relat protein bax bcl-2 hlm present serum result show patient protein band 180 kda kda frequent fisher p&lt 0.05 protein band 124 kda intens mann whitnei p&lt 0.05 healthi donor band 158 kda frequent fisher p&lt 0.05 band kda intens mann whitnei p&lt 0.05 band kda kda togeth frequent fisher p&lt 0.05 intens mann whitnei p&lt 0.05 bax bcl-2 hlm detect serum conclud chang serum protein pattern lung cancer patient detect simpl methodolog
arsen trioxid ato establish effect agent treat newli diagnos relaps acut promyelocyt leukemia apl patient laboratori data suggest ato induc apoptosi hematopoiet sever solid tumor cell howev date effect lung carcinoma fulli explor present studi investig effect ato human lung carcinoma cell vitro found ato significantli inhibit prolifer cell dose- time-depend manner ato-induc apoptosi cell confirm observ typic morpholog chang detect analysi flow cytometri fcm ato significantli inhibit bcl-2 pgp express cell sabc immunohistochemistri fcm analysi conclus find indic ato induc apoptosi cell down-regul bcl-2 pgp express data provid theoret basi clinic us treat lung carcinoma
conduct phase studi combin chemotherapi nedaplatin irinotecan cpt determin effect unresect non-small cell lung cancer nsclc determin qualit quantit toxic combin chemotherapi year older patient thirti-eight patient receiv 100 mg/m2 dai mg/m2 cpt dai everi four week twenti-five patient achiev nine three overal respons rate 65.8 nineteen patient experienc grade neutropenia neutropen fever occur patient on di grade non-hematolog toxic two patient experienc diarrhea on interstiti pneumon on liver injuri on rash median surviv time 418 dai on-year surviv rate 55.3 conclus combin cpt activ treatment elderli patient nsclc
tumor suppressor p53 protein neg regul mitogen-activ protein kinas mapk signal via induct mapk phosphatas recent describ mkp1 member mapk phosphatas famili transcription regul p53 via p53 respons element locat second intron mkp1 gene here identifi addit p53 respons element locat third exon mkp1 gene demonstr report gene assai p53 bind exon element transactiv mkp1 furthermor show exon respons element bound p53 both vitro vivo demonstr gel shift chip assai respect mutat exon intron site result ~50 decreas luciferas report activ loss both site complet abrog p53-depend transcript mkp1 result suggest element suffici confer p53 respons both element requir full activ result provid mechan p53 control transcript mkp1 gene
cyclooxygenas-2 cox2 plai crucial role lung carcinogenesi fact overexpress cox2 common non-small cell lung cancer nsclc seem associ tumor progress invas metastasi experiment anim model cox2 shown involv tumor angiogenesi suggest cox2 potenti target nsclc therapi sever vivo studi alreadi shown cox2 specif inhibitor celecoxib rofecoxib anti-tumor activ clinic trial us cox2 inhibitor current ongo patient nsclc
manag patient advanc non-small-cell lung cancer chang consider decad chemotherapi prolong surviv improv qualiti life patient good perform statu appear improv diseas-relat symptom patient lower perform statu platinum-base doublet remain standard regimen nonplatinum combin reason altern newer agent novel mechan action open area clinic research like improv outcom patient advanc non-small-cell lung cancer
background purpos us bleomycin blm import antineoplast drug usual limit develop dose time-depend interstiti pneumon pulmonari fibrosi.thi studi initi investig possibl protect effect acetyl-l-carnitin blm-induc lung toxic earli stage develop materi method total male spragu-dawlei rat weigh 200-250 divid group anim first group receiv daili i.p inject normal salin 0.5 ml/200 bodi weight consecut dai serv control anim second third fourth group daili inject intraperiton i.p blm mg/kg bodi weight 250 mg/kg bodi weight 250 mg/kg hr befor blm mg/kg consecut dai respect.result treatment rat blm mg/kg result signific 3.4 2.9 fold increas malondialdehyd mda nitric oxid product lung tissu respect signific decreas reduc glutathion gsh superoxid dismutas sod glutathion peroxidas gshpx adenosin triphosph atp respect compar control group treatment rat lead signific chang mention biochem paramet lung tissu administr two hour befor blm attenu blm-induc increas mda decreas gsh sod gshpx atp lung tissu conclus present data suggest protect effect blm-induc acut lung injuri least part due free radic scaveng properti consequ improv mitochondri function atp product
purpos studi conduct evalu success rate manag advanc lung cancer patient malign pleural effus compar talc powder tetracyclin pleurodesi patient method report patient lung cancer associ malign pleural effus treat depart surgeri nci cairo univers januari 1998 februari 2003 patient divid three group group pleurodesi us tetracyclin patient .group pleurodesi us talc slurri patient group iii pleurodesi us talc insuffl patient .good respons pleurodesi defin pleural fluid re-accumul minim pleural fluid re-accumul caus symptom requir aspir on month result male femal mean ag year rang 42-66 year right side effus present patient left side patient patholog subtyp adenocarcinoma patient squamou cell carcinoma undifferenti carcinoma patient group patient show good respons intrapleur tetracyclin patient respond group patient show good respons group iii post pleurodesi complic includ fever chest pain empyema conclus conclud studi thoracoscop talc insuffl effect easi low cost method produc pleurodesi patient recurr malign pleural effus prove better talc slurri tetracyclin
